PHASE II STUDY PS341 ALONE OR COMB W/ IRINOTECAN IN PATIENTS W/ ADENOCARCINOMA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 目的是：(1)确定伊立替康和PS341联合应用对未经治疗的胃食道连接部或胃腺癌患者的有效率；(2)确定PS341对既往治疗的胃食道交界部或胃腺癌患者的有效率，以及单独接受PS341或联合应用伊立替康的患者的毒副反应和转归；(3)对PS341治疗前后的活检标本进行基因芯片分析，以确定基因表达模式的变化。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Aims are: (1) to determine response rate for combination of irinotecan and PS341 in patients with previously untreated adenocarcinoma of gastroesophageal juntion or stomach; (2) to determine response rate for PS341 in patients with previously treated adenocarcinoma of the gastrophageal junction or stomach, the toxicities and recovery from toxicities for patients recieving PS341 alone or in combincation with irinotecan; and (3) to perform GeneChip analysis on biopsy specimens prior to and subsequent to treatment with PS341 to determine changes in patterns of gene espression.